# Sensitive Detection of DJ-1 in Artificial Cerebrospinal Fluid Using a Portable GPTMS-Coordinated Gold Nanoparticle-Based Biosensor

## TL;DR

A portable biosensor was developed to detect DJ-1, a Parkinson's disease biomarker, in artificial cerebrospinal fluid with high sensitivity and accuracy.

## Contribution

A novel GPTMS-coordinated gold nanoparticle-based biosensor for sensitive DJ-1 detection in artificial cerebrospinal fluid.

## Key findings

- The biosensor detected DJ-1 in the range of 0.001 to 0.3 ng/mL with a detection limit of 0.00059 ng/mL.
- The system showed recovery rates of 98.66% to 123.3% in artificial cerebrospinal fluid samples.
- Surface characterization confirmed successful modification and stability of the biosensor.

## Abstract

A highly selective and sensitive compact immunosensing strategy was developed for the determination of DJ-1, a potential biomarker of Parkinson’s disease, one of the leading neurodegenerative disorders, using a portable potentiostat. Initially, screen-printed carbon electrodes (SPCEs) were modified with gold nanoparticles (AuNPs), followed by functionalization with 4-mercapto-1-butanol (MOH). Subsequently, the AuNPs-doped and hydroxyl-functionalized electrodes were treated with 3-glycidoxypropyltrimethoxysilane (GPTMS) to facilitate immobilization of anti-DJ-1 antibodies. Immobilization steps were monitored using electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV) performed on a bench potentiostat, while the entire analytical performance of the developed biosensor system and its response in artificial cerebrospinal fluid (aCSF) were evaluated by monitoring cathodic current changes with a portable electrochemical reader. The resulting biorecognition element enabled the detection of DJ-1 within the concentration range of 0.001 to 0.3 ng/mL, based on cathodic current changes, achieving a limit of detection as low as 0.00059 ng/mL. Surface morphology and elemental composition alterations were characterized by scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), and energy-dispersive X-ray spectroscopy (EDX). A notable advantage of this GPTMS@AuNPs-based biosensor system is its prolonged storage stability and its capability to accurately quantify DJ-1 in artificial cerebrospinal fluid samples, with recovery rates ranging from 98.66% to 123.3%.